Medigen Vaccine Biologics Corporation
TWO: 6547.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leo Lee
- Employees
- 103
- Headquarters
- Taipei, Taiwan
- IPO year
- 2015
- Market cap
- NT$16.0B
- Website
- https://www.medigenvac.com
Loading 6547…
Loading profile data…Frequently asked questions about 6547
What does Medigen Vaccine Biologics Corporation (6547.TWO) do?
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical t...
Where does 6547.TWO trade?
Medigen Vaccine Biologics Corporation (6547.TWO) trades on the Taipei Exchange.
What sector is 6547.TWO in?
Medigen Vaccine Biologics Corporation (6547.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Medigen Vaccine Biologics Corporation?
Leo Lee is the chief executive officer of Medigen Vaccine Biologics Corporation (6547.TWO).
Where is Medigen Vaccine Biologics Corporation headquartered?
Medigen Vaccine Biologics Corporation is headquartered in Taiwan.
Does 6547.TWO pay a dividend?
Medigen Vaccine Biologics Corporation (6547.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6547.TWO go public?
Medigen Vaccine Biologics Corporation (6547.TWO) completed its initial public offering in 2015.